Yahoo! Finance: NYMX News

Nymox Pharmaceuticals gets $15M financing deal (AP)

Thu, 10 Dec 2009 21:06:34 Etc/GMT

Drug developer Nymox Pharmaceutical Corp. said Thursday it has obtained a commitment for $15 million in equity financing from institutional investors.

Nymox Announces New $15 Million Equity Financing Commitment (GlobeNewswire)

Thu, 10 Dec 2009 17:59:29 Etc/GMT

Nymox Releases Positive New Clinical Trial Data on Durability of Benefits for Early Responders to Company's BPH Drug NX-1207 (GlobeNewswire)

Mon, 23 Nov 2009 15:47:56 Etc/GMT

HASBROUCK HEIGHTS, N.J. -- Nymox Pharmaceutical Corporation announced today the release of positive new clinical trial data from responder analysis of the Company's pooled multi-center U.S.

Nymox Reports Third Quarter 2009 Financial Results (GlobeNewswire)

Fri, 13 Nov 2009 14:43:26 Etc/GMT

HASBROUCK HEIGHTS, N.J. -- Nymox Pharmaceutical Corporation announced today its financial results for the third quarter of 2009. Nymox reported a net loss of $1,362,840, or $0.04 per share for the quarter and $3,587,251, or $0.12 per share for the nine months ending September 30, 2009, compared to $1,318,293, or $0.04 per share for the quarter and $3,714,188, or $0.13 per share for the nine months ending September 30, 2008.

Piper Jaffray Senior Research Analyst Sees M&A Activity As Brisk As Foreign Companies Seek US Specialty Pharmaceutical Distribution Networks (Wall Street Transcript)

Fri, 13 Nov 2009 13:57:00 Etc/GMT

67 WALL STREET, New York - November 13, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Nymox's NX-1207 to be Clinically Tested for Prostate Cancer (GlobeNewswire)

Wed, 14 Oct 2009 15:22:40 Etc/GMT

Nymox Announces New Pooled Analysis Confirms 12 Month Benefit of NX-1207 Treatment for BPH (GlobeNewswire)

Mon, 5 Oct 2009 16:19:21 Etc/GMT

HASBROUCK HEIGHTS, N.J. -- Nymox Pharmaceutical Corporation is pleased to announce that a new formal statistical analysis of double-blind clinical trial data from pooled subjects in Phase 2 clinical trials for NX-1207, the Company's investigational treatment for BPH, confirmed that clinically significant benefits of a single NX-1207 treatment extend to 12 months or longer.

Nymox's NX-1207 Shows Major Effect On Liver Cancer (GlobeNewswire)

Wed, 26 Aug 2009 14:04:51 Etc/GMT

Nymox Reports Second Quarter 2009 Financial Results (GlobeNewswire)

Fri, 14 Aug 2009 13:22:53 Etc/GMT

9 Stocks to Shake the Market (at Motley Fool)

Wed, 24 Jun 2009 20:43:38 Etc/GMT

Nymox Announces Dosing of First Patient in Phase 3 Trial for NX-1207 for BPH (GlobeNewswire)

Tue, 2 Jun 2009 16:46:14 Etc/GMT

Nymox Reports First Quarter 2009 Financial Results (GlobeNewswire)

Fri, 15 May 2009 14:28:56 Etc/GMT

Nymox Announces Start of Second Phase 3 Trial for NX-1207 for BPH (GlobeNewswire)

Tue, 5 May 2009 14:51:46 Etc/GMT

Nymox Reports Initiation of Phase 3 Trials for NX-1207 for BPH (GlobeNewswire)

Tue, 21 Apr 2009 16:40:31 Etc/GMT

NYMOX PHARMACEUTICAL CORP Financials (EDGAR Online Financials)

Fri, 20 Mar 2009 13:04:20 Etc/GMT

Nymox Reports 2008 Financial Results (GlobeNewswire)

Fri, 13 Mar 2009 13:35:45 Etc/GMT

Nymox Announces New Positive Results At 5 Years After Single Treatment in Long Term Study of NX-1207 for Benign Prostatic Hyperplasia (GlobeNewswire)

Tue, 24 Feb 2009 18:05:15 Etc/GMT

Nymox Provides Update On Pivotal Phase 3 Trials for BPH Drug (GlobeNewswire)

Wed, 18 Feb 2009 16:55:25 Etc/GMT

Nymox Releases Positive New Clinical Trial Data On Durability of Response Rates to Company's BPH Drug NX-1207 (GlobeNewswire)

Tue, 13 Jan 2009 17:10:06 Etc/GMT

Third Hand Smoke Recognized as Health Hazard (GlobeNewswire)

Thu, 8 Jan 2009 16:43:33 Etc/GMT